Other products featured include: Radiosurgery collimator allows treatment of broad rang of tumors and Phi prostate cancer test and more.
San Diego-Imprimis Pharmaceuticals, Inc. has launched new compounded formulations for two urologic conditions-interstitial cystitis (IC) and erectile dysfunction (ED). Hep-Lido-A (alkalinized lidocaine and heparin) is a patented compounded formulation that is instilled directly into the bladder as an immediate treatment option for patients with IC. Hep-Lido-A’s new user-friendly kit includes a hydrophilic catheter and ready-to-use sterile pre-filled syringes (shown) compounded by an Imprimis pharmacy, providing convenience for in-office instillation and for patients who perform at-home instillations. Imprimis’ Tri-Mix (phentolamine, papaverine, and prostaglandin) lyophilized formulations are provided in a powder-like form in single-dose vials that can be transported and stored prior to reconstitution and self-administration for the treatment of ED. Tri-Mix formulations also allow for room-temperature storage. (Image via Imprimis Pharmaceuticals, Inc.)
For more information, visit www.imprimispharma.com.
Sunnyvale, CA-Accuray Inc. has introduced the InCise Multileaf Collimator (MLC) for the CyberKnife M6 radiosurgery system, which the company says is the first multileaf collimator to be available on a robotic platform. In evaluations completed by two U.S. sites, the main benefits of the MLC reported were the ability to treat a broader range of tumors than they could with fixed collimators or the Iris Collimator, and to do so with significantly increased efficiency. The CyberKnife M6 is designed to treat tumors anywhere in the body, including the prostate and kidney, according to Accuray. (Image via Accuray Inc)
For more information, visit www.accuray.com.
Rock Hill, SC-Physicians Choice Laboratory Services (PCLS) has added Beckman Coulter’s Prostate Health Index (phi) to the urologic health testing menu, providing access to physicians across the United States. The phi is a blood test that is three times more specific for the detection of prostate cancer than PSA alone, the only multi-analyte prostate cancer blood test with FDA approval, and the only multi-analyte blood test recommended in National Comprehensive Cancer Network Guidelines for prostate cancer early detection, according to PCLS. It helps physicians distinguish prostate cancer by combining three PSA markers (PSA, freePSA, and p2PSA) as part of an algorithm to accurately determine the probability of cancer in patients with elevated PSA levels and substantially reduce the number of negative biopsies.
(Image via Beckman Coulter’s Prostate Health Index, http://prostatehealthindex.us/)
For more information, www.pcls.com
Subscribe to Urology Times to get monthly news from the leading news source for urologists.